M
M. Cecilia Bahit
Researcher at Twitter
Publications - 28
Citations - 9057
M. Cecilia Bahit is an academic researcher from Twitter. The author has contributed to research in topics: Stroke & Atrial fibrillation. The author has an hindex of 17, co-authored 28 publications receiving 7869 citations.
Papers
More filters
Journal ArticleDOI
Apixaban versus Warfarin in Patients with Atrial Fibrillation
Christopher B. Granger,John H. Alexander,Renato D. Lopes,Elaine M. Hylek,Michael G. Hanna,Hussein R. Al-Khalidi,Jack Ansell,Dan Atar,Alvaro Avezum,M. Cecilia Bahit,Rafael Diaz,J. Donald Easton,Justin A. Ezekowitz,Greg C. Flaker,David A. Garcia,Margarida Geraldes,Bernard J. Gersh,Sergey P. Golitsyn,Shinya Goto,Antonio G. Hermosillo,Stefan H. Hohnloser,John D. Horowitz,Puneet Mohan,Petr Jansky,Basil S. Lewis,Jose Lopez-Sendon,Prem Pais,Alexander Parkhomenko,Jun Zhu,Lars Wallentin +29 more
TL;DR: In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.
Journal ArticleDOI
Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
J. Donald Easton,Renato D. Lopes,M. Cecilia Bahit,Daniel Wojdyla,Christopher B. Granger,Lars Wallentin,Marco Alings,Shinya Goto,Basil S. Lewis,Mårten Rosenqvist,Michael G. Hanna,Puneet Mohan,John H. Alexander,Hans-Christoph Diener +13 more
TL;DR: The effects of apixaban versus warfarin were consistent in patients with AF with and without previous stroke or TIA, and the absolute benefits of apxaban might be greater in this population.
Journal ArticleDOI
Post-Myocardial Infarction Heart Failure.
TL;DR: It is critical to frequently re-evaluate beta-blocker eligibility among patients after MI with HF, as the only therapy proven to reduce mortality for patients with cardiogenic shock is early revascularization.
Journal ArticleDOI
Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
Alvaro Avezum,Renato D. Lopes,Phillip J. Schulte,Fernando Lanas,Bernard J. Gersh,Michael G. Hanna,Prem Pais,Çetin Erol,Rafael Diaz,M. Cecilia Bahit,Jozef Bartunek,Raffaele De Caterina,Shinya Goto,Witold Rużyłło,Jun Zhu,Christopher B. Granger,John H. Alexander +16 more
TL;DR: There was no evidence of a differential effect of apixaban over warfarin in reducing stroke or systemic embolism, causing less bleeding, and reducing death in patients with and without valvular heart disease.
Journal ArticleDOI
Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial
Renato D. Lopes,Sana M. Al-Khatib,Lars Wallentin,Hongqiu Yang,Jack Ansell,M. Cecilia Bahit,Raffaele De Caterina,Paul Dorian,J. Donald Easton,Çetin Erol,Justin A. Ezekowitz,Bernard J. Gersh,Christopher B. Granger,Stefan H. Hohnloser,John D. Horowitz,Elaine M. Hylek,John J.V. McMurray,Puneet Mohan,Dragos Vinereanu,John H. Alexander +19 more
TL;DR: Apixaban significantly reduced stroke or systemic embolism with no evidence of a differential effect by risk of stroke, and patients who received apixaban had lower rates of major bleeding than did those who received warfarin.